Glenmark Pharmaceuticals today said it will cease sales of its morphine sulfate product in the US following a warning letter from USFDA.
"In compliance with the conditions of the warning letter, Glenmark will cease distribution of morphine sulfate product line within the time lines indicated by the USFDA," Glenmark said in a release.
Besides Glenmark, eight other companies have been issued warning letters on March 30.
Glenmark said non-sales of morphine would have a minimal impact on the company's finances.
Morphine Sulfate is an old drug and had been previously classified as "grandfathered" drug in the US.
In accordance with an FDA policy issued on June 2006, FDA is going for transition of 'grandfathered' products to FDA-approved new drug application, Glenmark said.
